In the PERTAIN study, the PFS was 18.9 months/15.8 months in patients with HER2+ HR+ metastatic breast cancer/locally advanced breast cancer who received trastuzumab + aromatase inhibitor (AI) with/without pertuzumab, respectively [14]. The gene discussed is ERBB2; the disease is breast cancer.